Dose selection and tolerability of anticancer agents evaluated by the European Medicines Agency in the period 2015-2020

Abstract

The dose-response relationship has not been established for the majority of the registered anticancer agents. The selected posology is often poorly tolerable as reflected by the high discontinuation and dose reduction rates. Due to the absence of dose-response data, it is often unknown if the optimal dose has been selected for anticancer agents.